Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vixotrigine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 18/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 0.98 |
| ▸ | SCN4A | P35499 | 1/20 | 0.98 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.98 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.98 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.98 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.98 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vixotrigine SCHEMBL840484 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL841096 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL20562288 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL29388010 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL840179 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL4446697 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL2831660 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL862301 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL311438 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL311437 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812048-B | Preparation method of sodium ion channel retarder CNV1014802 hydrochloride form | 北京蓝博特科技有限公司 | 2022-08-26 | — | — | CN | claimed |
| US-20220098150-A1 | Novel Crystalline Forms | BIOGEN MA INC. | 2022-03-31 | — | — | US | claimed |
| US-20200147041-A1 | PAROXYSMAL EXTREME PAIN DISORDER TREATMENT | Convergence Pharmaceuticals Limited (GB) | 2020-05-14 | — | — | US | claimed |
| CN-110913852-A | Novel crystalline forms | 生物基因麻省公司 | 2020-03-24 | — | — | CN | claimed |
| US-20200062705-A1 | NOVEL CRYSTALLINE FORMS | BIOGEN INC. | 2020-02-27 | — | — | US | claimed |
| EP-3200783-B1 | ERYTHROMELALGIA TREATMENT | CONVERGENCE PHARMACEUTICALS (GB) | 2019-07-31 | — | — | EP | claimed |
| EP-3200785-B1 | PAROXYSMAL EXTREME PAIN DISORDER TREATMENT | CONVERGENCE PHARMACEUTICALS (GB) | 2019-07-31 | — | — | EP | claimed |
| EP-3200784-B1 | SMALL FIBRE NEUROPATHY TREATMENT | CONVERGENCE PHARMACEUTICALS (GB) | 2019-07-31 | — | — | EP | claimed |
| US-20170304264-A1 | Novel Erythromelalgia Treatment | Convergence Pharmaceuticals Limited (GB) | 2017-10-26 | — | — | US | claimed |
| US-20170304265-A1 | Paroxysmal Extreme Pain Disorder Treatment | Convergence Pharmaceuticals Limited (GB) | 2017-10-26 | — | — | US | claimed |
| US-8153681-B2 | Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | claimed |
| US-8143306-B2 | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (GB) | 2012-03-27 | — | — | US | claimed |
| US-20110098335-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-04-28 | — | — | US | claimed |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | claimed |
| US-7655693-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | claimed |
| US-20080280969-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2008-11-13 | — | — | US | claimed |
| EP-1943216-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | claimed |
| EP-1934177-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-06-25 | — | — | EP | claimed |
| WO-2007042239-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | claimed |
| WO-2007042250-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098150-A1 | Novel Crystalline Forms | SCN5A, HCN4, SCN4A | SCN9A 11/4885KCNH2 20/4885SCN3A 7/4885 |
| US-20110098335-A1 | NOVEL COMPOUNDS | SCN1A, SCN1B, SCNN1B | SCN9A 35/4885KCNH2 65/4885SCN3A 8/4885 |
| US-20200062705-A1 | NOVEL CRYSTALLINE FORMS | SCN5A, KCNQ5, HCN4 | SCN9A 11/4885KCNH2 23/4885SCN3A 5/4885 |
| US-20170304265-A1 | Paroxysmal Extreme Pain Disorder Treatment | PEPD, FAP, PREP | SCN9A 75/4885KCNH2 348/4885SCN3A 17/4885 |
| US-20080280969-A1 | Novel Compounds | CYP11B2, CYP46A1, SLC10A1 | SCN9A 1889/4885KCNH2 1998/4885SCN3A 2634/4885 |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | SCN5A, SCN1A, SCN7A | SCN9A 14/4885KCNH2 58/4885SCN3A 6/4885 |
| US-20170304264-A1 | Novel Erythromelalgia Treatment | TYR, PAH, EGLN3 | SCN9A 1753/4885KCNH2 3226/4885SCN3A 1019/4885 |
| US-20200147041-A1 | PAROXYSMAL EXTREME PAIN DISORDER TREATMENT | PEPD, FAP, PREP | SCN9A 75/4885KCNH2 348/4885SCN3A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.